<?xml version="1.0" encoding="UTF-8"?>
<p>The risk of HBV reactivation can be divided into high risk ( ≥ 10%), moderate risk (1%–10%), and low risk ( &lt; 1%) based on the type of immunosuppressive therapy used, which was stratified by HBsAg-positive, or HBsAg-negative plus anti-HBc positive [
 <xref rid="b83-ir-2019-09155" ref-type="bibr">83</xref>,
 <xref rid="b98-ir-2019-09155" ref-type="bibr">98</xref>,
 <xref rid="b99-ir-2019-09155" ref-type="bibr">99</xref>]. Prophylactic therapy with potent oral antiviral agents to treat HBV is highly recommended in patients at high or moderate risk of reactivation. In contrast, close monitoring for HBV reactivation is recommended in patients at low risk of reactivation. The risk of HBV reactivation is listed in 
 <xref rid="t3-ir-2019-09155" ref-type="table">Table 3</xref>.
</p>
